Radiation plus two cancer drugs tested in advanced liver cancer trial

NCT ID NCT05488522

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tests whether adding precise radiation (SBRT) to a standard two-drug combination (atezolizumab and bevacizumab) is safe and tolerable for people with advanced liver cancer that cannot be treated with surgery. The trial enrolls 18 participants and will also look at how well the tumors respond. The goal is to find a dose and schedule for future larger studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Stereotactic body radiotherapy (SBRT) plus atezolizumab and bevacizumab
What this could lead to
If successful, this could point toward a new combination treatment that helps control advanced liver cancer when standard therapies are no longer effective.
What could go wrong
This is a very early (phase I) trial with only 18 participants, focused on safety and dosing. It is not designed to prove the combination works, and side effects from radiation or the drugs could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Abramson Cancer Center of the University of Pennsylvania

    RECRUITING

    Philadelphia, Pennsylvania, 19104-4283, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.